Dr. Krishna Gundabolu, MD

Dr. Gundabolu practices at Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System.

Dr. Gundabolu's NPI, 1710250899, was assigned on February 20, 2012. Dr. Gundabolu holds Nebraska license 27263.

Dr. Gundabolu's primary practice is Nebraska Medical Center, at 988102 Nebrasks Medical Center, Omaha, NE 68198 in Douglas County. The practice phone is (402) 559-4000. Dr. Gundabolu also practices at Nebraska Medical Center, 987400 Nebraska Medical Ctr, Omaha, NE 68198.

Dr. Gundabolu's primary practice is Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System. Dr. Gundabolu is also affiliated with Bellevue Medical Center. The medical group on file is UNMC Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gundabolu practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gundabolu's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Gundabolu's licenses on file in 2 states: Nebraska and Minnesota.

CMS data shows 1,042 Medicare services from Dr. Gundabolu across 8 procedure codes in 2024, for 227 Medicare patients. Medicare paid $64,213 for them.

CMS counts 227 Medicare patients who saw Dr. Gundabolu in 2024. The largest group is 65 to 74, with 119 patients. 74% of them have high blood pressure, and 68% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gundabolu's median patient age at 71, with 47% women.

In 2024, Dr. Gundabolu wrote 1,359 Medicare Part D claims for 143 patients. 60% of them were for generic drugs. CMS names the drug for 1,074 of them, across 33 drugs with 11 or more claims each, at $4,017,195 in total drug cost. In 2023, CMS named 1,229 claims across 34 drugs.

Dr. Gundabolu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gundabolu as offering telehealth.

Dmand AI links 60 papers to Dr. Gundabolu, published from 2013 to 2025. 2019 was the busiest year, with 8. The most frequent topics are Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute and Comorbidity. Dr. Gundabolu has published most often in Leuk Lymphoma. Dr. Gundabolu's most frequent co-authors are Vijaya Raj Bhatt, MD, Prajwal Dhakal, MBBS and James O. Armitage, MD.

Dmand AI links Dr. Gundabolu to 11 clinical trials, 4 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Burkitt Lymphoma, Epstein-Barr Virus Infections and Intracranial Embolism and Thrombosis. National Cancer Institute (NCI) sponsors the most, 3. Open Payments lists research payments to Dr. Gundabolu that name 1 trial.

CMS Open Payments shows 99 general payments to Dr. Gundabolu from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Novartis Pharmaceuticals Corporation paid the most, $18,171. It also lists 24 research payments totaling $39,040 in 2016, naming 1 clinical trial.